British pharmaceutical giant GSK Plc (NYSE:GSK) on Wednesday reported fourth-quarter core earnings of 68 cents (25.5 pence), outperforming the consensus forecast of 64 cents. Earnings jumped 10% or 14% at constant currency (cc).
GSK stock is trading higher than the 52-week range of $32.38-$53.38.
GSK’s fourth-quarter sales reached $11.46 billion (8.62 billion British pounds). That’s an 8% increase cc, exceeding analyst estimates of $11.19 billion.
Vaccine sales edged 4% higher (+4% cc) to 2.29 billion pounds. The increase was driven by strong ex-U.S. demand for Shingrix, Arexvy, and Meningitis vaccines, partly offset by lower U.S. demand for Shingrix, Arexvy, and Influenza vaccines, as well as lower International sales of Established vaccines.
Growth in the quarter also benefited from higher Shingrix sales in China.
Shingrix vaccine sales were up 20% to 1.01 billion pounds.
Arexvy sales reached 198 million pounds, up 25%. Meningitis vaccine sales increased 6% to 313 million, while established vaccine sales of 694 million decreased 14% (-13% cc).
Specialty Medicines sales grew by 15% (+18% cc) in the quarter to 3.81 billion pounds.
General Medicines sales decreased by 3% (-1% cc) to 2.52 billion pounds.
“GSK delivered another strong performance in 2025, driven mainly by Specialty Medicines, with double-digit sales growth in Respiratory, Immunology & Inflammation (RI&I), Oncology and HIV…” said Luke Miels, CEO, GSK.
The board declared a fourth interim dividend of 18 pence per share for the fourth quarter of 2025, up from 16 pence a year earlier.
Guidance
“We expect this positive momentum to continue in 2026, which will be a key year of execution and operational delivery with strong focus on commercial launches and accelerating R&D. We are well placed to move forward in this next phase for GSK – to deliver our outlooks – and to create new value for patients and shareholders,” Miels commented.
GSK forecasts fiscal 2026 sales to increase between 3% and 5%. Specialty Medicine sales are expected to increase in low double-digits.
The company expects sales from vaccines and general medicine to decline by a low single digit to stable.
The company expects core operating profit and earnings per share to increase between 7% and 9%.
For fiscal 2031, GSK sees sales of more than 40 billion pounds.
GSK Price Action: Gsk shares were up 4.07% at $55.51 during premarket trading on Wednesday. The stock is trading at a new 52-week high, according to Benzinga Pro data.
Photo via Shutterstock
